Kevin Dennis Green Sells 60,656 Shares of Cerus Co. (NASDAQ:CERS) Stock

Cerus Co. (NASDAQ:CERS) CFO Kevin Dennis Green sold 60,656 shares of the firm’s stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $1.58, for a total transaction of $95,836.48. Following the sale, the chief financial officer now owns 493,862 shares of the company’s stock, valued at $780,301.96. This represents a 10.94 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Cerus Stock Down 5.0 %

Cerus stock opened at $1.53 on Friday. Cerus Co. has a fifty-two week low of $1.38 and a fifty-two week high of $2.59. The company has a debt-to-equity ratio of 1.19, a quick ratio of 1.92 and a current ratio of 2.59. The firm has a 50 day moving average price of $1.74 and a 200 day moving average price of $1.80. The company has a market capitalization of $284.26 million, a PE ratio of -13.91 and a beta of 1.29.

Cerus (NASDAQ:CERS) last posted its earnings results on Thursday, February 20th. The biotechnology company reported ($0.01) earnings per share for the quarter, meeting the consensus estimate of ($0.01). Cerus had a negative net margin of 11.60% and a negative return on equity of 40.55%. The firm had revenue of $50.81 million during the quarter, compared to the consensus estimate of $50.81 million. Research analysts expect that Cerus Co. will post -0.08 earnings per share for the current year.

Analysts Set New Price Targets

Separately, Cantor Fitzgerald reiterated an “overweight” rating and issued a $4.00 target price on shares of Cerus in a report on Friday, February 21st.

Hedge Funds Weigh In On Cerus

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Geode Capital Management LLC boosted its position in Cerus by 1.6% in the 3rd quarter. Geode Capital Management LLC now owns 4,415,453 shares of the biotechnology company’s stock valued at $7,685,000 after buying an additional 69,950 shares during the period. State Street Corp boosted its position in Cerus by 2.2% in the 3rd quarter. State Street Corp now owns 3,738,893 shares of the biotechnology company’s stock valued at $6,506,000 after buying an additional 79,505 shares during the period. Barclays PLC boosted its position in Cerus by 16.2% in the 3rd quarter. Barclays PLC now owns 1,575,049 shares of the biotechnology company’s stock valued at $2,740,000 after buying an additional 219,755 shares during the period. Stifel Financial Corp boosted its position in Cerus by 12.0% in the 3rd quarter. Stifel Financial Corp now owns 264,672 shares of the biotechnology company’s stock valued at $461,000 after buying an additional 28,383 shares during the period. Finally, ARK Investment Management LLC boosted its position in Cerus by 14.2% in the 4th quarter. ARK Investment Management LLC now owns 20,814,752 shares of the biotechnology company’s stock valued at $32,055,000 after buying an additional 2,589,721 shares during the period. Hedge funds and other institutional investors own 78.37% of the company’s stock.

About Cerus

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.